All In Biotech

Free tool

FAERS Monitor: Orilissa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210450 or its brand name (Orilissa, Elagolix Sodium). Reports on generic versions are filed under their own applications.

Reports

3,729

Serious

1,319

35% of reports

Hospitalization

321

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hot flush471
  • pain437
  • nausea327
  • endometriosis304
  • headache277
  • drug ineffective253
  • depression214
  • arthralgia200
  • anxiety163
  • insomnia151
  • suicidal ideation148
  • adverse drug reaction140
  • fatigue137
  • surgery136
  • mood swings115

Reports by year received

View as table
YearReports
201849
2019930
20201,090
2021517
2022700
2023223
2024121
202575
202624

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,430 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endometriosisSignal304384.0343.4108,399
hot flushSignal47135.532.615,698
mood swingsSignal11520.417.12,100
surgerySignal13613.111.11,510
suicidal ideationSignal1489.17.81,067
adverse drug reactionSignal1408.87.5963
depressionSignal2145.34.7752
painSignal4374.03.71,015
anxietySignal1633.22.8252
insomniaSignal1513.22.7229
arthralgiaSignal2002.72.4219
headacheSignal2772.52.2254
nauseaSignal3272.32.1257
drug ineffective2531.11.02
fatigue1371.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.